Jennifer Cochran, Ph.D. has served in numerous roles at Stanford University since 2005, where she is currently the Addie and Al Macovski Professor of Bioengineering, and (by courtesy) Chemical Engineering, and Vice President for SLAC National Linear Accelerator Laboratory and for Strategic Initiatives. She is a founding member of the Stanford Bioengineering Department and served as its Chair from 2017 to 2022, and was a Senior Associate Vice Provost of Research at Stanford from 2022 to 2026. Dr. Cochran co-founded Red Tree Venture Capital, a life-sciences-focused investment fund, in 2020 and serves as its Chief Scientific Advisor. Dr. Cochran formerly served as Chief Scientist of Lagunita Biosciences, a healthcare investment company and incubator, from October 2015 to April 2020. Dr. Cochran currently serves on the boards of directors of privately-held biotechnology companies Biograph 55, Kivu Bioscience, Revel Pharmaceuticals, and Rondo Therapeutics, and is a board observer at Excellergy Therapeutics and Ebvio Inc. She previously served as a member of the board of directors of Ligand Pharmaceuticals Incorporated and on the boards of directors of privately-held biotechnology companies she founded including Combangio, Inc. (acquired by Kala Bio in 2021), as well as xCella Biosciences until its acquisition by Ligand Pharmaceuticals in 2020. Dr. Cochran received a B.S. degree in biochemistry from the University of Delaware and a Ph.D. in biological chemistry and a postdoctoral fellowship in biological engineering from the Massachusetts Institute of Technology. Dr. Cochran s extensive bioengineering background and knowledge of the biopharmaceutical industry contributed to our board of directors conclusion that she should serve as a director of our company.